Search Results

This article explores Johns Hopkins University’s unique approach to recruiting specialists outside the field of oncology to participate in its virtual immune-related Toxicity Team.

This article explores how Jefferson Health is taking a unique approach to recruiting specialists outside the field of oncology to participate in an Immuno-oncology Working Group.

This article explores how Cleveland Clinic is taking a unique approach to recruiting specialists outside the field of oncology to participate in immunotherapy multispecialty immune-related adverse events (irAE) tumor boards.

How do interest specialists outside the field of oncology in participating in an inter-specialty immune-related adverse events (irAEs) tumor board? Cleveland Clinic discovered the key is to recruit physician champions who are not oncologists.

At Jefferson Health, detecting, diagnosing, and monitoring immune-related adverse events (irAEs) that may results from treatment with immunotherapies for cancer is a group effort. To provide scheduling flexibility and the ability to respond to queries as they arise, the 11-member Jefferson Immuno-Oncology Working groups meets online on an as-needed basis.

Johns Hopkins was one of the first institutions to use immunotherapies to treat intractable cancers. Because IO therapies can affect any of the body's organ systems, there was early recognition of the value of having a multidisciplinary team of organ specialists who could bring their expertise to the treatment of patients experiencing immune-related adverse events (irAEs).

As immunotherapies are increasingly used for patients with difficult-to-treat cancers, oncologists are challenged to identify the specialist expertise they need to address the immune-related adverse events (irAEs) that can accompany these therapies. While cancer programs seek to build effective strategies to create a team approach toward managing irAEs, some are creating a virtual space in which multiple …